TOBRAMYCIN SULFATE Drug Patent Profile
✉ Email this page to a colleague
When do Tobramycin Sulfate patents expire, and what generic alternatives are available?
Tobramycin Sulfate is a drug marketed by Apothecon, Baxter Hlthcare Corp, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hainan Poly, Hikma, Hospira, Igi Labs Inc, Mylan Labs Ltd, Teva Pharms Usa, Watson Labs Inc, Xellia Pharms Aps, and Xgen Pharms. and is included in thirty-two NDAs.
The generic ingredient in TOBRAMYCIN SULFATE is tobramycin sulfate. There are eighteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tobramycin sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tobramycin Sulfate
A generic version of TOBRAMYCIN SULFATE was approved as tobramycin sulfate by HIKMA on April 26th, 1991.
Summary for TOBRAMYCIN SULFATE
US Patents: | 0 |
Applicants: | 15 |
NDAs: | 32 |
Finished Product Suppliers / Packagers: | 11 |
Raw Ingredient (Bulk) Api Vendors: | 135 |
Clinical Trials: | 5 |
Patent Applications: | 4,224 |
Formulation / Manufacturing: | see details |
DailyMed Link: | TOBRAMYCIN SULFATE at DailyMed |
Recent Clinical Trials for TOBRAMYCIN SULFATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Madonna Magdy Fahmy | Early Phase 1 |
Osteal Therapeutics, Inc. | Phase 2 |
Joint Purification Systems | Phase 2 |
Pharmacology for TOBRAMYCIN SULFATE
Drug Class | Aminoglycoside Antibacterial |